Skip to main content
Equibles

ABVX · Abivax S.A. · Metrics

Track ABVX — free

Use ABVX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ABVX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$90.20 -1.24 (-1.36%) At close · Nov 12 Q4 2023 earnings call transcript
Rebalance outlook locked
Market Cap
$7.90B
Shares
87.54M
Volume · Nov 12 692.05K Avg daily vol (3M) 1.09M

ABVX metrics

65 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$90.20
Market cap
$7.90B

Price action

23 metrics
Price change (1W)
+2.2%
Price change (30D)
+6.1%
Price change (3M)
-27.2%
Price change (6M)
-25.0%
Price change (YTD)
-32.2%
Price change (1Y)
-16.2%
Trailing year
Price change (5Y)
—
52-week high
$145.31
52-week low
$72.50
Change from 52-week high
-37.1%
Change from 52-week low
+26.1%
Annualized volatility
86.6%
Annualized volatility (3M)
45.7%
Implied volatility (30D)
70.4%
IV rank (1Y)
12.8
IV percentile (1Y)
35.3
Beta
1.2
RSI (14D)
51.7
Price vs SMA 50
-4.5%
Price vs SMA 200
-18.9%
Avg volume (3M)
1.09M
Relative volume
0.7
Average dollar volume
$109.07M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
87.54M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1,363.9×
reciprocal yield 0.1%
P / book
19.1
reciprocal yield 5.2%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-12-14
Last earnings
2026-09-21

Profitability

9 metrics
Gross margin
—
Operating margin
-5,821.4%
Trailing 12 months
Net margin
-7,979.7%
Gross profit (TTM)
—
Operating profit (TTM)
−$292.70M
Net income (TTM)
−$467.93M
Trailing 12 months
Diluted EPS (TTM)
$-6.20
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$5.80

Growth

11 metrics
Revenue growth YoY
+9.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$5.87M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+24.0%
Year over year · more shares
Revenue CAGR (3Y)
-0.1%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-109.5%
Return on assets
-86.8%
Debt / equity
—
Current ratio
6.0
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
6.0
Interest coverage
-2.0
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$442.97M
Total assets
$527.70M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$229.93M
Capital expenditures (TTM)
$285,791
R&D (TTM)
$242.27M
SG&A (TTM)
—
Stock compensation (TTM)
−$102.17M
R&D / revenue
4,130.7%
Stock compensation / revenue
-1,740.4%

Ownership (13F)

9 metrics
13F filers
308
13F filer change QoQ
+51
Institutional ownership
76.1%
Conviction holders (share of 13F filers)
12.3%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+7.4%
Holder tenure
5.4
Price vs estimated holder cost
+54.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.7%

Short interest

3 metrics
Short interest
4.7%
Latest settlement · 4.6 days to cover
Days to cover
4.6d
Short-squeeze score
56 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1956827 CUSIP 00370M103 13F (30d) 161 filings 153 filers Visit website Investor relations